Cargando…
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the liver without fibrosis, has been regarded as a benign disease in the past, but it is now known to be prognostic. In...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029939/ https://www.ncbi.nlm.nih.gov/pubmed/36503207 http://dx.doi.org/10.3350/cmh.2022.0357 |
_version_ | 1784910247518797824 |
---|---|
author | Nogami, Asako Yoneda, Masato Iwaki, Michihiro Kobayashi, Takashi Honda, Yasushi Ogawa, Yuji Imajo, Kento Saito, Satoru Nakajima, Atsushi |
author_facet | Nogami, Asako Yoneda, Masato Iwaki, Michihiro Kobayashi, Takashi Honda, Yasushi Ogawa, Yuji Imajo, Kento Saito, Satoru Nakajima, Atsushi |
author_sort | Nogami, Asako |
collection | PubMed |
description | Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the liver without fibrosis, has been regarded as a benign disease in the past, but it is now known to be prognostic. In the future, more emphasis should be placed on the quantification of liver fat. Traditionally, fatty liver has been assessed by histological evaluation, which requires an invasive examination; however, technological innovations have made it possible to evaluate fatty liver by non-invasive imaging methods, such as ultrasonography, computed tomography, and magnetic resonance imaging. In addition, quantitative as well as qualitative measurements for the detection of fatty liver have become available. In this review, we summarize the currently used qualitative evaluations of fatty liver and discuss quantitative evaluations that are expected to further develop in the future. |
format | Online Article Text |
id | pubmed-10029939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Korean Association for the Study of the Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-100299392023-03-22 Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Nogami, Asako Yoneda, Masato Iwaki, Michihiro Kobayashi, Takashi Honda, Yasushi Ogawa, Yuji Imajo, Kento Saito, Satoru Nakajima, Atsushi Clin Mol Hepatol Review Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the liver without fibrosis, has been regarded as a benign disease in the past, but it is now known to be prognostic. In the future, more emphasis should be placed on the quantification of liver fat. Traditionally, fatty liver has been assessed by histological evaluation, which requires an invasive examination; however, technological innovations have made it possible to evaluate fatty liver by non-invasive imaging methods, such as ultrasonography, computed tomography, and magnetic resonance imaging. In addition, quantitative as well as qualitative measurements for the detection of fatty liver have become available. In this review, we summarize the currently used qualitative evaluations of fatty liver and discuss quantitative evaluations that are expected to further develop in the future. The Korean Association for the Study of the Liver 2023-02 2022-12-12 /pmc/articles/PMC10029939/ /pubmed/36503207 http://dx.doi.org/10.3350/cmh.2022.0357 Text en Copyright © 2023 by The Korean Association for the Study of the Liver https://creativecommons.org/licenses/by-nc/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Nogami, Asako Yoneda, Masato Iwaki, Michihiro Kobayashi, Takashi Honda, Yasushi Ogawa, Yuji Imajo, Kento Saito, Satoru Nakajima, Atsushi Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future |
title | Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future |
title_full | Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future |
title_fullStr | Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future |
title_full_unstemmed | Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future |
title_short | Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future |
title_sort | non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029939/ https://www.ncbi.nlm.nih.gov/pubmed/36503207 http://dx.doi.org/10.3350/cmh.2022.0357 |
work_keys_str_mv | AT nogamiasako noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture AT yonedamasato noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture AT iwakimichihiro noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture AT kobayashitakashi noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture AT hondayasushi noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture AT ogawayuji noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture AT imajokento noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture AT saitosatoru noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture AT nakajimaatsushi noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture |